October 24, 2008 -
Preservation with BioLife’s Proprietary, Next Generation, Biopreservation Media Resulted in Increased Yield and Quality of Insulin-Producing Islet Cells – BioLife Solutions Inc. (OTCBB: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, announced that MicroIslet Inc. (OTCBB: MIIS), a biotechnology company engaged in developing and commercializing cellular therapies for patients with diabetes, has adopted HypoThermosol for preserving, transporting, and storing pancreatic source material.
MicroIslet plans to isolate and encapsulate islet cells for the treatment of Type 1 diabetic patients under a planned investigational new drug application and subsequent clinical trial...
BioLife Solutions' Press Release -
October 24, 2008 - Preservation with BioLife’s Proprietary, Next Generation, Biopreservation Media Resulted in Increased Yield and Quality of Insulin-Producing Islet Cells – BioLife Solutions Inc. (OTCBB: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, announced that MicroIslet Inc. (OTCBB: MIIS), a biotechnology company engaged in developing and commercializing cellular therapies for patients with diabetes, has adopted HypoThermosol for preserving, transporting, and storing pancreatic source material.
MicroIslet plans to isolate and encapsulate islet cells for the treatment of Type 1 diabetic patients under a planned investigational new drug application and subsequent clinical trial... BioLife Solutions' Press Release -
